Research and Studies
Rheumatoid arthritis drug upadacitinib boosts alopecia areata regrowth
Phase 3 data suggest upadacitinib may restore at least 80% scalp coverage in many people with severe alopecia areata within 24 weeks.
By the Thicker Thinking Editorial Team
Published · 5 min read
Quick answerA large phase 3 trial found the rheumatoid arthritis pill upadacitinib helped roughly half of people with severe alopecia areata regain at least 80% scalp coverage in 24 weeks. Eyebrow and eyelash growth also improved, according to Medical News Today.
A rheumatoid arthritis pill has shown notable results in a major trial for severe alopecia areata, helping many participants regain substantial scalp coverage within six months. Researchers reported that upadacitinib led to at least 80% scalp hair coverage in about half of those treated at 24 weeks, according to Medical News Today.
Beyond scalp hair, the study also recorded gains in eyebrows and eyelashes and improvements in social and emotional wellbeing. Upadacitinib, a Janus kinase (JAK) inhibitor, has since been approved in Europe for severe alopecia areata in adults and adolescents, Medical News Today reported.
What happened
Researchers ran a randomised phase 3 clinical trial enrolling almost 1,400 people, including adults and adolescents, with severe alopecia areata. Participants received daily oral upadacitinib at two different dose strengths and were followed for 24 weeks.
At the end of the 24-week period, around half of the group on the lower dose achieved hair regrowth covering at least 80% of the scalp. In the higher-dose group, 54% reached the same level of coverage, according to Medical News Today’s reporting of the study findings.
Non‑scalp hair also responded. Investigators observed improvements in eyebrows and eyelashes, outcomes many people prioritise for day‑to‑day confidence. Quality‑of‑life measures improved alongside physical regrowth, suggesting meaningful benefit beyond hair counts.
Upadacitinib acts on the JAK‑STAT signalling pathway, which drives inflammatory activity implicated in alopecia areata. The authors described the response profile as showing “rapid onset and substantial depth of response,” reflecting the speed and scale of regrowth seen in the trial.
Although the trial was not designed to compare medicines head‑to‑head, the proportions achieving high levels of regrowth place upadacitinib among the more effective systemic options studied so far in severe alopecia areata, based on the trial’s reported outcomes.
Regulatory progress has followed quickly in some regions. Medical News Today noted that the medicine now has European approval for severe alopecia areata in adults and adolescents. A US Food and Drug Administration review is in progress.
As with all systemic immunomodulators, safety and monitoring remain central. Dermatologists generally assess infection risk, review medical history and medicines, and monitor blood tests during JAK inhibitor treatment. These checks aim to balance potential benefits with known class risks such as infections and cardiovascular concerns.
The background
Alopecia areata is an autoimmune condition in which the immune system targets hair follicles, causing patchy hair loss on the scalp and sometimes the brows, lashes and body. About 160 million people worldwide are affected, Medical News Today reported.
Patterns vary widely, from one or two coin‑sized patches to loss across the scalp or entire body. Early recognition and diagnosis are important; our explainer on hair loss in small patches: causes, signs and next steps outlines the typical features and when to seek advice.
The condition can affect self‑image and mental health at any age. In the UK, legal recognition of the impact has been highlighted in recent cases; our analysis of whether female hair loss can be a disability explores the wider consequences and support routes.
Current treatments include topical and injected corticosteroids, contact immunotherapy and systemic agents, including JAK inhibitors, for more extensive disease. Responses vary, and no treatment is curative; relapses can occur, and some people do not respond sufficiently to existing options.
Upadacitinib is already licensed for several inflammatory conditions, including rheumatoid arthritis, atopic dermatitis and inflammatory bowel disease. Repurposing medicines with known mechanisms and safety profiles is a common strategy when biology overlaps between conditions.
It is also important to recognise that some rheumatoid arthritis medicines can themselves contribute to hair thinning. Everydayhealth.com reports that methotrexate has been linked to hair thinning in around 9% of users, leflunomide affects about one in 10, and anti‑TNF biologics have been associated with hair loss in a smaller proportion of women.
Autoimmune conditions often cluster. Everydayhealth.com notes that people with rheumatoid arthritis appear to have a higher risk of developing alopecia areata, and thyroid disease—particularly autoimmune thyroiditis—is more common in rheumatoid arthritis and can add to hair loss risk.
Stress, both physical and emotional, can trigger a temporary shedding called telogen effluvium, which may overlay alopecia areata. Our guide to stress and hair loss: signs, timing and recovery explains how to recognise and manage this pattern while other treatments are considered.
Because everyday shedding varies, it can be hard to judge what is normal. Our overview of how much hair loss is normal — and when to worry sets out typical ranges and red flags that suggest a need for medical review.
What people are saying
The study’s lead author described the results as showing “rapid onset and substantial depth of response,” underscoring both speed and magnitude of regrowth reported in the trial.
Dermatologists generally advise confirming the diagnosis and mapping the pattern and extent of loss before starting any systemic therapy. This often includes checking for other autoimmune conditions, reviewing medications and discussing goals such as scalp, brow and lash regrowth.
Specialists typically weigh the benefits and risks of JAK inhibitors for each person, including infection risk, cardiovascular profile and vaccination status. Regular follow‑up and blood tests are standard to ensure treatment remains both effective and safe over time.
For people with rheumatoid arthritis who notice new shedding, clinicians advise speaking to the prescribing team before altering any medication. Doctors may consider dose adjustments, switching medicines or supportive measures such as folate supplementation where appropriate, alongside dermatology referral if alopecia areata is suspected.
Appearance‑focused support remains important whatever the medical plan. NHS wig services can help with temporary or longer‑term options; our guide to NHS wigs, costs and help with charges outlines eligibility and practical steps.
What happens next
With European approval granted, attention now turns to regulatory and access decisions elsewhere. In the US, an FDA review is under way. In the UK, any move towards routine NHS use would typically require Medicines and Healthcare products Regulatory Agency approval and cost‑effectiveness appraisal.
Researchers will be looking for longer‑term data on maintenance of regrowth, relapse rates after stopping treatment and safety over extended periods. Studies comparing upadacitinib with other JAK inhibitors or immunotherapies could clarify where it best fits in treatment pathways.
For individuals noticing patchy loss, first steps are a GP appointment and, where needed, referral to a dermatologist or trichologist. Keeping a simple timeline of changes and any new medications can help clinicians assess triggers and choose next steps, as discussed in our overview of alopecia types and warning signs.
The inclusion of adolescents in the trial suggests potential across age groups, though treatment for under‑18s is usually specialist‑led and carefully monitored. Families are encouraged to seek expert advice early to discuss the safest and most appropriate options for their situation.
Why this matters
For people in the UK living with alopecia areata, a systemic option that delivers meaningful regrowth within months could widen choices when first‑line treatments fall short. Access will depend on regulatory and NHS decisions, and safety monitoring matters. If you notice patchy loss, speak to your GP about a dermatology referral and discuss support such as wigs while exploring treatments. Our guide to hair loss in small patches, causes and next steps can help you prepare for that appointment.
Common questions
- does a rheumatoid arthritis drug help alopecia areata
- Yes. A phase 3 trial found the RA pill upadacitinib helped many people with severe alopecia areata regain at least 80% scalp coverage within 24 weeks, according to Medical News Today.
- how effective is upadacitinib for alopecia areata
- In the trial, about half on the lower dose and 54% on the higher dose achieved at least 80% scalp coverage at 24 weeks, researchers reported.
- how quickly did hair regrowth happen with upadacitinib
- The main results were assessed at 24 weeks. Investigators described the response as rapid, with substantial regrowth by that point, according to Medical News Today.
- is upadacitinib approved for alopecia areata in europe or the uk
- Medical News Today reports European approval for severe alopecia areata in adults and adolescents. UK access would require separate regulatory and NHS assessments.
- does alopecia areata affect eyebrows and eyelashes too
- Yes. The condition can involve brows and lashes, and the trial reported improvements in these areas alongside scalp regrowth.
- can rheumatoid arthritis medications cause hair loss
- Some can. Everydayhealth.com notes methotrexate and leflunomide can cause thinning, and a smaller proportion of women on anti‑TNF biologics reported hair loss.
- what are the risks of jak inhibitors for hair loss treatment
- JAK inhibitors are systemic immunomodulators, so clinicians monitor for infections, blood abnormalities and cardiovascular risks. Dermatologists assess suitability and arrange regular safety checks.
- who should i see if i think i have alopecia areata
- Start with your GP. They can assess and, if needed, refer you to a dermatologist or trichologist to confirm the diagnosis and discuss treatment options.
Sources
- Medical News Today: Alopecia areata: Rheumatoid arthritis drug may treat hair loss
- everydayhealth.com: Rheumatoid Arthritis: Understanding the Causes and Remedies for Hair Loss
This article was written by Thicker Thinking using the sources listed above. It is for general information and is not medical advice. Speak to your GP, a dermatologist or a qualified trichologist about your own situation.
